A first for Fast Track designation

A first for Fast Track designation

September 14, 2016

Caladrius Biosciences recently announced that its product candidate CLBS03 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of type 1 diabetes mellitus (TID), making it the first known therapeutic candidate for T1D to receive the designation.

Click here to read the full article